Adrion, Christine


  • Adrion C, Fischer CS, Wagner J, Mansmann U, Strupp M; on behalf of the BEMED study group. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016; 352:h6816. DOI: http://dx.doi.org/10.1136/bmj.h6816 (Published 21 January 2016)

  • Feil K, Adrion C, Teufel J, Bösch S, Claassen C, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Stendel C, Uslar E, Warrenburg B, Berger I, Naumann I, Bayer O, Müller HH, Mansmann U, Strupp M. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurology 2017; 17(1):7.

  • Brenner C, Adrion C, Grabmaier U, Theisen D, von Ziegler F, Leber A, Becker A, Sohn HY, Hoffmann E, Mansmann U, Steinbeck G, Franz WM, Theiss HD. SITAgliptin plus GRanulocyte colony-stimulating factor in patients suffering from Acute Myocardial Infarction: A double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial). Int J Cardiol 2016 Feb 15; 205:23-30. DOI: 10.1016/j.ijcard.2015.11.180. Epub 2015 Nov 30.

  • Gross L, Theiss HD, Grabmaier U, Adrion C, Mansmann U, Sohn HY, Hoffmann E, Steinbeck G, Franz WM, Brenner C. Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction – Long-term results of the SITAGRAMI Trial. Int J Cardiol 2016 Jul 15; 215:441-445. DOI: 10.1016/j.ijcard.2016.04.134.

  • Bender A, Adrion C, Fischer L, Huber M, Jawny K, Straube A, Mansmann U. Long-term rehabilitation in patients with acquired brain injury: A randomized controlled trial of an intensive, participation-focused outpatient treatment program [Langzeitrehabilitation von Patienten mit erworbenen Hirnschädigungen: Eine randomisierte kontrollierte Studie zu einem intensiven teilhabeorientierten ambulanten Therapieprogramm]. Dtsch Arztebl Int 2016; 113:634-41.

  • Hüfner K, Frenzel C, Kremmyda O, Adrion C, Bardins S, Glasauer S, Brandt T, Strupp M. Esophoria or esotropia in adulthood – a sign of cerebellar dysfunction? J Neurol 2015; 262(3):585-92.

  • Schwab F, Ingrisch M, Marcus R, Bamberg F, Hildebrand K, Adrion C, Gliemi C, Nikolaou K, Reiser M, Theisen D. Tracer kinetic modeling in myocardial perfusion quantification using magnetic resonance imaging. Magnetic Resonance in Medicine 2015; 73(3):1206-15.

  • Neugebauer H, Adrion C, Glaser M, Strupp M. Long-term changes of central ocular motor signs in patients with vestibular migraine. Eur Neurol 2013; 69(2):102-107.

  • Adrion C, Mansmann U. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: An example from a vertigo phase III study with longitudinal count data as primary endpoint. BMC Medical Research Methodology 2012 Sep 10; 12(1):137. DOI: 10.1186/1471-2288-12-137

  • Schniepp R, Wuehr M, Neuhaeusser M, Benecke AK, Adrion C, Brandt T, Strupp M, Jahn K. 4-aminopyridine and cerebellar gait – a retrospective case series. J Neurol 2012; 259(11):2491-3.

  • Fritsche LG, Fleckenstein M, Fiebig BS, Schmitz-Valckenberg S, Bindewald-Wittich A, Keilhauer CN, Renner AB, Mackensen F, Mößner A, Pauleikhoff D, Adrion C, Mansmann U, Scholl HP, Holz FG, Weber BHF. A subgroup of age-related macular degeneration is associated with mono-allelic sequence variants in the ABCA4 gene. Invest Ophthalmol Vis Sci 2012; 53(4):2112-2118.

  • Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77(3):269-75.

  • Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Visvalingam S, Göbel AP, Mössner A, von Strachwitz CN, Mackensen F, Pauleikhoff D, Wolf S, Mansmann U, Holz FG; FAM Study Group. Progression of age-related geographic atrophy: role of the fellow eye. Invest Ophthalmol Vis Sci 2011; 52(9):6552-7.

  • Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière's disease: a case series. Eur Arch Otorhinolaryngol 2011; 268(8):1237-40.

  • Brinkmann CK, Adrion C, Mansmann U, Schmitz-Valckenberg S, Holz FG. Clinical characteristics, progression and risk factors of geographic atrophy. Ophthalmologe 2010; 107(11):999-1006.

  • Fleckenstein M, Schmitz-Valckenberg S, Adrion C, Krämer I, Eter N, Helb HM, Brinkmann CK, Charbel Issa P, Mansmann U, Holz FG. Tracking progression with spectral-domain optical coherence tomography in geographic atrophy caused by age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51(8):3846-52.

  • Fleckenstein M*, Adrion C*, Schmitz-Valckenberg S, Göbel AP, Bindewald-Wittich A, Scholl HP, Mansmann U, Holz FG; FAM Study Group. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 2010; 51(2):637-42.
    *Contributed equally to the work and therefore should be considered equal authors. 
  • Scholl HP, Fleckenstein M, Fritsche LG, Schmitz-Valckenberg S, Göbel A, Adrion C, Herold C, Keilhauer CN, Mackensen F, Mössner A, Pauleikhoff D, Weinberger AW, Mansmann U, Holz FG, Becker T, Weber BH. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One 2009; 4(10):e7418.

  • Hüfner K, Barresi D, Glaser M, Linn J, Adrion C, Mansmann U, Brandt T, Strupp M. Vestibular paroxysmia: diagnostic features and medical treatment. Neurology 2008; 71(13):1006-14.

  • Mansmann U, Crispin A, Henschel V, Adrion C, Augustin V, Birkner B, Munte A. Epidemiology and Quality Control of 245000 Outpatient Colonoscopies. Dtsch Arztebl 2008; 105(24):434-40.

Letter to the Editor

Adrion C, Strupp M, Mansmann U. Lessons learned from a recent superiority trial on intratympanic injections in refractory unilateral Meniere’s disease? Commentary on Patel et al. BMJ Rapid Response (electronic letter to the editor), 12 March 2017, http://www.bmj.com/content/355/bmj.i6185/rr

Adrion C, Mansmann U. Question about primary outcome definition in the BEMED trial: Author response. BMJ Rapid Response (electronic letter to the editor), 24 November 2017, http://www.bmj.com/content/352/bmj.h6816/rr-3